| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jun 19, 2020
PHILADELPHIA--(June 19, 2020) – The University City Science Center announces the election of two new Board members, following the 2020 Annual Meeting of Shareholders held on June 19th: Yi Deng,...
-
Jun 12, 2020Global bleeding disorders community will connect and discuss treatment advances June 14-19, 2020
KING OF PRUSSIA, Pa - June 12 2020 - Global biotherapeutics leader CSL Behring announced today that the company will both attend and sponsor the World Federation of Hemophilia (WFH) first ever...
-
Jun 8, 2020Investigational Monoclonal Antibody Granted U.S. FDA Orphan Drug Designation
HATTERSHEIM, Germany – 8 June 2020 – CSL Behring, a global biotherapeutics leader, today announced results of a Phase 2 clinical trial for garadacimab (previously known as CSL312), an...
-
Jun 8, 2020• Builds on CSL Behring’s promise and commitment to the transplant community
KING OF PRUSSIA, Pa. – 8 June 2020 – Global biotherapeutics leader CSL Behring announced today that it has agreed to acquire Vitaeris Inc., a clinical-stage biotechnology company focused on...
Jun 2, 2020Initially, the alliance will develop treatment options for patients with two rare, life-threatening primary immunodeficiency diseases -- Wiskott-Aldrich Syndrome (WAS) and X-linked Agammaglobulinemia (XLA)SEATTLE and KING of PRUSSIA, Pa. – June 02, 2020 - Seattle Children’s Research Institute, one of the top pediatric research institutions in the world, and global biotechnology leader CSL...
-
May 27, 2020Thermo Fisher Scientific Inc. and CSL Limited have entered into a strategic partnership to help meet the growing demand for biologic therapies while also accelerating CSL’s broader manufacturing objectives.
WALTHAM, Mass. and KING OF PRUSSIA, Penn. 27 May 2020 Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, and global biotechnology company, CSL Limited...
-
May 26, 2020“The Fight Is In Us” Campaign Seeks to Mobilize COVID-19 Survivors to Accelerate the Development of Potentially Lifesaving Therapies
Redmond, Wash., USA, and New York 26 May 2020 A coalition of world-leading medical and research institutions, blood centers, life science companies, technology companies, philanthropic...
-
May 7, 2020- Rapidly expanding support for the Alliance is increasing donations of convalescent plasma to begin clinical production, while NIH collaboration confirms clinical trial approach
Osaka, JAPAN, and King of Prussia, PA, USA – 7 May 2020 – The CoVIg-19 Plasma Alliance, an unprecedented plasma industry collaboration recently established to accelerate the development of a...
-
Apr 21, 2020Study examined the safety and tolerability of faster infusion rates and higher infusion volumes, as well as the feasibility of a new manual push administration method
PHILADELPHIA, PA – April 21, 2020 – Global biotherapeutics leader CSL Behring today announced that a clinical study examining faster infusion rates and higher volumes than currently approved...
-
Apr 8, 2020COVID-19 treatment candidate, a high-potency immunotherapy delivering human polyclonal antibodies targeted to SARS-CoV-2, generated from SAB’s novel platform technology, on-track for clinical evaluation as early as summer
King of Prussia, Pa. and Sioux Falls, S.D. 08 Apr 2020 Global biotherapeutics leader, CSL Behring and innovative human antibody development company SAB Biotherapeutics (SAB) announced today their...